Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/5255
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTripathi, C K M-
dc.contributor.authorTripathi, Divya-
dc.contributor.authorPraveen, Vandana-
dc.contributor.authorBihari, Vinod-
dc.date.accessioned2009-07-14T06:08:59Z-
dc.date.available2009-07-14T06:08:59Z-
dc.date.issued2007-04-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/5255-
dc.description326-332en_US
dc.description.abstractBiodiversity is an addition sum of the studies on genetic, taxonomic commercial and ecosystem aspects of living systems. All the living individuals of a species contain a distinct combination of genes and the intrinsic interaction among the gene pool influences evolution, survival and phenotypic/genotypic changes of the part of the biodiversity i.e. community. The amount of genetic diversity within population varies tremendously and much of modern conservation biology is concerned with the maintenance of genetic diversity within the population of plants, animals and microbes. Germplasm, obtained with the vast biodiversity, provides a major source of biological material for the development of medicines, vaccines, pharmaceutical products, improved crop and animal varieties and for other environmental applications. Industrialized nations, who have the technology and resources to patent and develop commercial biological products, are having the benefits of biodiversity through the collected and conserved germplasm flowing through the international research centers. In fact a particular genetic contribution usually represents only a small percentage of the total value of the eventual products. In addition, the research and development process required to commercialize a particular product requires enormous technical efforts. The principle of patenting genes is the morally or ethically correct is a matter of intense debate. However, geneticists, having conceived of the technologies with vast and immediate therapeutic, food and environmental values must try to bring to the material to market as soon as possible.en_US
dc.language.isoen_USen_US
dc.publisherCSIRen_US
dc.sourceIJEB Vol.45(04) [April 2007]en_US
dc.subjectCommunity structureen_US
dc.subjectEconomic valueen_US
dc.subjectEcosystemen_US
dc.subjectGenomeen_US
dc.subjectMetagenomicsen_US
dc.subjectMolecular diversityen_US
dc.subject16S rRNAen_US
dc.titleMicrobial diversity – Biotechnological and industrial perspectivesen_US
dc.typeArticleen_US
Appears in Collections:IJEB Vol.45(04) [April 2007]

Files in This Item:
File Description SizeFormat 
IJEB 45(4) 326-332.pdf99.13 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.